Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 91

1.

A Survey of Molecular Heterogeneity in Hepatocellular Carcinoma.

Jovel J, Lin Z, O'keefe S, Willows S, Wang W, Zhang G, Patterson J, Moctezuma-Velázquez C, Kelvin DJ, Ka-Shu Wong G, Mason AL.

Hepatol Commun. 2018 Jul 12;2(8):941-955. doi: 10.1002/hep4.1197. eCollection 2018 Aug.

2.

New perspectives on the complexity of genetic predisposition to autoimmune liver disease in indigenous Canadians.

Mason AL, Siminovitch KA.

Liver Int. 2018 May;38(5):789-791. doi: 10.1111/liv.13722. No abstract available.

PMID:
29702744
3.

An assessment of nutrients and sedimentation in the St. Thomas East End Reserves, US Virgin Islands.

Pait AS, Galdo FR Jr, Ian Hartwell S, Apeti DA, Mason AL.

Environ Monit Assess. 2018 Apr 9;190(5):270. doi: 10.1007/s10661-018-6628-0.

PMID:
29633032
4.

Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS).

Nguyen HH, Shaheen AA, Baeza N, Lytvyak E, Urbanski SJ, Mason AL, Norman GL, Fritzler MJ, Swain MG.

PLoS One. 2018 Mar 19;13(3):e0193960. doi: 10.1371/journal.pone.0193960. eCollection 2018.

5.

Recurrence of primary biliary cholangitis after liver transplantation: A Japanese perspective.

Montano-Loza AJ, Mason AL.

Hepatol Commun. 2017 Jul 7;1(5):391-393. doi: 10.1002/hep4.1058. eCollection 2017 Jul. No abstract available.

6.

Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.

Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Dalekos GN, Bruns T, Parés A, Mason AL, Verhelst X, Kowdley KV, Goet JC, Hirschfield GM, Hansen BE, van Buuren HR.

Am J Gastroenterol. 2018 Feb;113(2):254-264. doi: 10.1038/ajg.2017.440. Epub 2017 Dec 12.

PMID:
29231188
7.

Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis.

Alberts R, de Vries EMG, Goode EC, Jiang X, Sampaziotis F, Rombouts K, Böttcher K, Folseraas T, Weismüller TJ, Mason AL, Wang W, Alexander G, Alvaro D, Bergquist A, Björkström NK, Beuers U, Björnsson E, Boberg KM, Bowlus CL, Bragazzi MC, Carbone M, Chazouillères O, Cheung A, Dalekos G, Eaton J, Eksteen B, Ellinghaus D, Färkkilä M, Festen EAM, Floreani A, Franceschet I, Gotthardt DN, Hirschfield GM, Hoek BV, Holm K, Hohenester S, Hov JR, Imhann F, Invernizzi P, Juran BD, Lenzen H, Lieb W, Liu JZ, Marschall HU, Marzioni M, Melum E, Milkiewicz P, Müller T, Pares A, Rupp C, Rust C, Sandford RN, Schramm C, Schreiber S, Schrumpf E, Silverberg MS, Srivastava B, Sterneck M, Teufel A, Vallier L, Verheij J, Vila AV, Vries B, Zachou K; International PSC Study Group, The UK PSC Consortium, Chapman RW, Manns MP, Pinzani M, Rushbrook SM, Lazaridis KN, Franke A, Anderson CA, Karlsen TH, Ponsioen CY, Weersma RK.

Gut. 2018 Aug;67(8):1517-1524. doi: 10.1136/gutjnl-2016-313598. Epub 2017 Aug 4.

8.

Glycogen synthase kinase 3β inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism.

Sarhan MA, Abdel-Hakeem MS, Mason AL, Tyrrell DL, Houghton M.

Sci Rep. 2017 May 31;7(1):2495. doi: 10.1038/s41598-017-02648-6.

9.

Cerebrospinal Fluid in a Small Cohort of Patients with Multiple Sclerosis Was Generally Free of Microbial DNA.

Jovel J, O'keefe S, Patterson J, Bording-Jorgensen M, Wang W, Mason AL, Warren KG, Wong GK.

Front Cell Infect Microbiol. 2017 Jan 6;6:198. doi: 10.3389/fcimb.2016.00198. eCollection 2016.

10.

Systematic review: recurrent autoimmune liver diseases after liver transplantation.

Montano-Loza AJ, Bhanji RA, Wasilenko S, Mason AL.

Aliment Pharmacol Ther. 2017 Feb;45(4):485-500. doi: 10.1111/apt.13894. Epub 2016 Dec 12. Review.

11.

An assessment of butyltins and metals in sediment cores from the St. Thomas East End Reserves, USVI.

Hartwell SI, Apeti DA, Mason AL, Pait AS.

Environ Monit Assess. 2016 Nov;188(11):642. Epub 2016 Oct 27.

PMID:
27787748
12.

Characterization of the Gut Microbiome Using 16S or Shotgun Metagenomics.

Jovel J, Patterson J, Wang W, Hotte N, O'Keefe S, Mitchel T, Perry T, Kao D, Mason AL, Madsen KL, Wong GK.

Front Microbiol. 2016 Apr 20;7:459. doi: 10.3389/fmicb.2016.00459. eCollection 2016.

13.

Combination antiretroviral studies for patients with primary biliary cirrhosis.

Lytvyak E, Montano-Loza AJ, Mason AL.

World J Gastroenterol. 2016 Jan 7;22(1):349-60. doi: 10.3748/wjg.v22.i1.349. Review.

14.

Mucosal Barrier Depletion and Loss of Bacterial Diversity are Primary Abnormalities in Paediatric Ulcerative Colitis.

Alipour M, Zaidi D, Valcheva R, Jovel J, Martínez I, Sergi C, Walter J, Mason AL, Wong GK, Dieleman LA, Carroll MW, Huynh HQ, Wine E.

J Crohns Colitis. 2016 Apr;10(4):462-71. doi: 10.1093/ecco-jcc/jjv223. Epub 2015 Dec 9.

15.

Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.

Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, Floreani A, Ponsioen CY, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Burroughs AK, Mason AL, Kowdley KV, Kumagi T, Harms MH, Trivedi PJ, Poupon R, Cheung A, Lleo A, Caballeria L, Hansen BE, van Buuren HR; Global PBC Study Group.

Gastroenterology. 2015 Dec;149(7):1804-1812.e4. doi: 10.1053/j.gastro.2015.07.061. Epub 2015 Aug 7.

PMID:
26261009
16.

Time to make the change from 'primary biliary cirrhosis' to 'primary biliary cholangitis'.

Cheung AC, Montano-Loza A, Swain M, Vincent C, Renner E, Sherman M, Janssen HL, Mason AL.

Can J Gastroenterol Hepatol. 2015 Aug-Sep;29(6):293. Epub 2015 Jul 21. No abstract available.

17.

Metagenomic analysis of microbiome in colon tissue from subjects with inflammatory bowel diseases reveals interplay of viruses and bacteria.

Wang W, Jovel J, Halloran B, Wine E, Patterson J, Ford G, OʼKeefe S, Meng B, Song D, Zhang Y, Tian Z, Wasilenko ST, Rahbari M, Reza S, Mitchell T, Jordan T, Carpenter E, Madsen K, Fedorak R, Dielemann LA, Ka-Shu Wong G, Mason AL.

Inflamm Bowel Dis. 2015 Jun;21(6):1419-27. doi: 10.1097/MIB.0000000000000344.

18.

Role of novel retroviruses in chronic liver disease: assessing the link of human betaretrovirus with primary biliary cirrhosis.

Sharon D, Mason AL.

Curr Infect Dis Rep. 2015 Feb;17(2):460. doi: 10.1007/s11908-014-0460-7.

19.

Editorial: Betaretrovirus in biliary epithelia of patients with autoimmune and cryptogenic liver disease - authors' reply.

Wang W, Indik S, Wong GK, Mason AL.

Aliment Pharmacol Ther. 2015 Mar;41(5):491. doi: 10.1111/apt.13082. No abstract available.

20.

Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study.

Trivedi PJ, Lammers WJ, van Buuren HR, Parés A, Floreani A, Janssen HL, Invernizzi P, Battezzati PM, Ponsioen CY, Corpechot C, Poupon R, Mayo MJ, Burroughs AK, Nevens F, Mason AL, Kowdley KV, Lleo A, Caballeria L, Lindor KD, Hansen BE, Hirschfield GM; Global PBC Study Group.

Gut. 2016 Feb;65(2):321-9. doi: 10.1136/gutjnl-2014-308351. Epub 2015 Jan 7.

PMID:
25567117

Supplemental Content

Loading ...
Support Center